title: Variation of adverse drug reaction profile of platinum-based chemotherapy with body mass index in patients with solid tumors: an observational study.
abstract: OBJECTIVE
  Toxicity of cancer chemotherapy may be affected by nutritional status of patients which is reflected in the body mass index (BMI). We sought to assess whether the adverse drug reaction (ADR) profile of platinum-based chemotherapy varies with BMI status.
  
  
  METHODS
  Adult patients of either sex, suffering from a solid tumor (lung, head and neck, ovary, gall bladder, stomach, colon) and started on platinum-based chemotherapy as initial treatment were included. BMI at chemotherapy commencement was obtained from medical records. Events were recorded and graded as per Eastern Co-operative Oncology Group Common Toxicity Criteria-patients' complaints; clinically evident signs and laboratory reports were considered. Frequencies of individual adverse events were compared between low BMI (<18.5 kg/m(2)) and satisfactory BMI groups. Similar comparisons were done for events with grades 2 or 3 severities.
  
  
  RESULTS
  A total of 50 patients were observed over a 3-month period of whom 17 (34%) belonged to the low BMI group. Nausea, vomiting, diarrhea, stomatitis, anemia, alopecia, tinnitus and paresthesia were the commonly observed ADRs. The frequencies of anemia (P = 0.152) and vomiting (P = 0.140) and severity of grades of nausea (P = 0.066), anemia (P = 0.120) and paresthesia (P = 0.128) showed a higher trend in the low BMI group though differences were not statistically significant. The frequencies of tinnitus (P = 0.021) and paresthesia overall (P = 0.036) were significantly higher in the low BMI group.
  
  
  CONCLUSIONS
  ADR profile of primary platinum-based chemotherapy appears to be partly influenced by BMI. This suggests the importance of maintaining adequate nutrition in patients and the need for greater vigilance in those with low BMI.
authors.affiliation: Department of Pharmacology, R. G. Kar Medical College and Hospital, Kolkata, West Bengal, India.
authors.forename: Dattatreyo
authors.initials: D
authors.lastname: Chatterjee
authors.affiliation: Department of Radiotherapy, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India.
authors.forename: Somnath
authors.initials: S
authors.lastname: Roy
authors.affiliation: Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India.
authors.forename: Avijit
authors.initials: A
authors.lastname: Hazra
authors.affiliation: Department of Radiotherapy, R. G. Kar Medical College and Hospital, Kolkata, West Bengal, India.
authors.forename: Partha
authors.initials: P
authors.lastname: Dasgupta
authors.affiliation: Department of Radiotherapy, R. G. Kar Medical College and Hospital, Kolkata, West Bengal, India.
authors.forename: Subir
authors.initials: S
authors.lastname: Ganguly
authors.affiliation: Department of Pharmacology, R. G. Kar Medical College and Hospital, Kolkata, West Bengal, India.
authors.forename: Anup Kumar
authors.initials: AK
authors.lastname: Das
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015992:Body Mass Index; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077150:Oxaliplatin; D012720:Severity of Illness Index
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D016190:Carboplatin; D002945:Cisplatin
keywords: Adverse drug reaction; body mass index; platinum-based chemotherapy; solid tumor
references.citation: Radiother Oncol. 2002 Feb;62(2):185-9
references.pmid: 11937245
references.citation: Am J Clin Oncol. 1982 Dec;5(6):649-55
references.pmid: 7165009
references.citation: Clin Oncol (R Coll Radiol). 2007 Feb;19(1):23-37
references.pmid: 17305252
references.citation: J Clin Oncol. 2004 Feb 15;22(4):648-57
references.pmid: 14966087
references.citation: Leuk Lymphoma. 2014 Aug;55(8):1743-50
references.pmid: 24128069
references.citation: Clin Cancer Res. 2007 Jun 1;13(11):3264-8
references.pmid: 17545532
references.citation: Colorectal Dis. 2010 Oct;12(10 Online):e190-9
references.pmid: 19895595
references.citation: Ann Oncol. 2010 Aug;21(8):1594-1598
references.pmid: 20089558
references.citation: Cancer Chemother Pharmacol. 1998;42(5):386-90
references.pmid: 9771953